Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Retained Earnings (2017 - 2025)

Historic Retained Earnings for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to -$1.3 billion.

  • Crinetics Pharmaceuticals' Retained Earnings fell 4916.55% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 4916.55%. This contributed to the annual value of -$952.1 million for FY2024, which is 4564.89% down from last year.
  • As of Q3 2025, Crinetics Pharmaceuticals' Retained Earnings stood at -$1.3 billion, which was down 4916.55% from -$1.2 billion recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Retained Earnings' 5-year high stood at -$190.5 million during Q1 2021, with a 5-year trough of -$1.3 billion in Q3 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' median Retained Earnings value was -$536.1 million (recorded in 2023), while the average stood at -$609.4 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first tumbled by 7138.5% in 2021, then tumbled by 4555.06% in 2025.
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' Retained Earnings stood at -$275.3 million in 2021, then crashed by 59.55% to -$439.2 million in 2022, then tumbled by 48.85% to -$653.7 million in 2023, then tumbled by 45.65% to -$952.1 million in 2024, then plummeted by 36.54% to -$1.3 billion in 2025.
  • Its last three reported values are -$1.3 billion in Q3 2025, -$1.2 billion for Q2 2025, and -$1.0 billion during Q1 2025.